Abstract
Background: TG4001 is a vaccine targeting HPV E6 and E7. It has shown to provide histological clearance of cervical pre-cancerous lesions (Harper DM et al. 2019). We aimed to evaluate in the Ph Ib part the safety of TG4001 in combination with avelumab in HPV 16-positive cancers (NCT03260023). Method(s): Patients with HPV-16 positive cancers who had received
Cite
CITATION STYLE
Le Tourneau, C., Delord, J.-P., Cassier, P., Loirat, D., Tavernaro, A., Bastien, B., & Bendjama, K. (2019). Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers. Annals of Oncology, 30, v494–v495. https://doi.org/10.1093/annonc/mdz253.036
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
